Targeting the <i>Apoa1</i> locus for liver-directed gene therapy.
Ontology highlight
ABSTRACT: Clinical application of somatic genome editing requires therapeutics that are generalizable to a broad range of patients. Targeted insertion of promoterless transgenes can ensure that edits are permanent and broadly applicable while minimizing risks of off-target integration. In the liver, the Albumin (Alb) locus is currently the only well-characterized site for promoterless transgene insertion. Here, we target the Apoa1 locus with adeno-associated viral (AAV) delivery of CRISPR-Cas9 and achieve rates of 6% to 16% of targeted hepatocytes, with no evidence of toxicity. We further show that the endogenous Apoa1 promoter can drive robust and sustained expression of therapeutic proteins, such as apolipoprotein E (APOE), dramatically reducing plasma lipids in a model
SUBMITTER: De Giorgi M
PROVIDER: S-EPMC8166646 | biostudies-literature | 2021 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA